Issue 1,646: August 10, 2022
Top Stories Pages and Handouts
Featured Resources
Notable Publications
Upcoming Events
Top Stories releases new “Vaccines: Monkeypox" main page connecting you to resources from CDC, FDA,, and professional organizations released its new Vaccines: Monkeypox main page that provides links to key monkeypox vaccine resource pages from CDC, FDA,, and other professional organizations. Information is provided about the live, non-replicating vaccine against monkeypox and smallpox, Jynneos (Bavarian Nordic), the primary vaccine used to prevent monkeypox, as well as the alternative live, replication competent vaccinia vaccine, ACAM2000 (Emergent). 

Bookmark's new Vaccines: Monkeypox main page for key links to important resources. The page will be updated as new guidelines and resources for vaccine administration are developed.

Related Links

Back to top
HHS Secretary declares monkeypox a public health emergency to strengthen and accelerate the federal response

On August 4, U.S. Department of Health and Human Services Secretary Xavier Becerra declared the monkeypox outbreak in the United States a Public Health Emergency (PHE). The declaration strengthened and accelerated the federal government’s response to monkeypox in the United States and globally. Portions of the press release are reprinted below:

The PHE declaration is in concert with the Food and Drug Administration’s (FDA) work to explore new strategies that could help get vaccines to affected communities across the country...

The public health emergency also carries important implications for data sharing with the federal government. Fifty-one jurisdictions have already signed data use agreements that will provide the Centers for Disease Control and Prevention (CDC) with information related to vaccine administration. Declaring the outbreak an emergency may provide the justification that the remaining jurisdictions need to sign their agreements. Additionally, it provides authorities to the Centers for Medicare & Medicaid Services to collect testing and hospitalization data.

Related Links

Back to top issues important update of “Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools.” Check your document versions today. offers a four-page job aid, Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools, to help you keep up with changes to COVID-19 vaccine guidance and resources. The checklist includes the most recent revision dates of CDC’s primary COVID-19 vaccination websites, as well as print-ready PDF documents from CDC and FDA. Each date is hyperlinked to the original document or web page. updates this list at least monthly, prominently indicating when it was last updated at the top of the page.

The current checklist, updated through August 3, 2022, was expanded to include each of the important documents related to the recent addition of Novavax COVID-19 Vaccine as an option for primary series vaccination of adults. We encourage COVID-19 vaccination providers to review this checklist each time it is revised to be sure practices stay up to date. 

Related Links

“Interim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19 Vaccine in Persons Aged ≥18 Years—United States, July 2022” published in MMWR

CDC published Interim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19 Vaccine in Persons Aged ≥18 Years—United States, July 2022 in the August 5 issue of MMWR. A portion of the summary appears below.

On July 13, 2022, the Food and Drug Administration issued Emergency Use Authorization for the NVX-CoV2373 (Novavax) COVID-19 vaccine....

On July 19, 2022, the Advisory Committee on Immunization Practices made an interim recommendation for use of the Novavax vaccine in persons aged ≥18 years as a primary 2-dose series vaccination for the prevention of COVID-19....

The adjuvanted, protein subunit–based Novavax COVID-19 vaccine provides an additional option for unvaccinated adults, increasing flexibility for the public and for vaccine providers. Vaccination is important for protection against COVID-19.

Access the MMWR article in HTML or PDF.

Related Link

Hepatitis B Foundation releases its National Immunization Awareness Month Partner Toolkit 2022 with resources for providers and content for sharing on social media

In recognition of National Immunization Awareness Month, the Hepatitis B Foundation created a partner toolkit for social media and promotional materials for the universal adult hepatitis B vaccination recommendation. Featured in the toolkit are social media graphics, sample social media posts, posters, and a hepatitis B vaccine record card. 

View the toolkit.

Related Links

Spotlight:’s “Standing Orders Templates for Administering Vaccines” main page helps you simplify your vaccination practice’s Standing Orders Templates for Administering Vaccines main page includes 46 straightforward standing order templates that allow qualified healthcare professionals to assess the need for and administer vaccines to patients meeting certain criteria, such as age or underlying medical condition. In addition to templates developed by, the page includes links to CDC’s standing orders templates for all COVID-19 vaccines and all age groups, as well as CDC’s new standing orders template for monkeypox vaccination with Jynneos (Bavarian Nordic).

Standing orders help you increase vaccination rates by enabling assessment and vaccination of the patient without the need for clinician examination or a direct order from the attending provider at the time of the interaction. Standing orders can be established for the administration of one or more specific vaccines to a broad or narrow set of patients in healthcare settings such as clinics, hospitals, pharmacies, and long-term care facilities.

Visit the Standing Orders Templates for Administering Vaccines main page on to view the standing orders templates.

Back to top

Vaccines in the news

These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.

Back to top Pages and Handouts updates its online clinical questions and answers on its "Ask the Experts: Haemophilus influenzae type b (Hib)" web page

On July 31, posted its updated clinical questions and answers about Hib vaccination in its popular web section, Ask the Experts: Haemophilus influenzae type b (Hib). regularly reviews and updates its content to ensure it stays current. You can find more than 1,200 Q&As about other vaccines and vaccine administration on our "Ask the Experts" main page at's team of experts includes Kelly L. Moore, MD, MPH (team lead), Carolyn B. Bridges, MD, FACP, and Iyabode Beysolow, MD, MPH.

Related Links

Back to top updates printable "Zoster Vaccine: Answers Your Questions" to encourage vaccination of immunocompromised people age 19 and older recently updated its Zoster Vaccine: Answers Your Questions printable resource for healthcare personnel. It now incorporates the recommendation to give Shingrix routinely to immunocompromised people age 19 and older, and adds two references that provide more detail on this recommendation.

Related Links

Back to top revises “When Do Children and Teens Need Vaccinations?” to include the routine recommendation for COVID-19 vaccination of children age 6 months and older updated When Do Children and Teens Need Vaccinations? to indicate that COVID-19 vaccine is routinely recommended for infants and children, beginning at age 6 months.

Related Links updates "Hepatitis B and Healthcare Personnel" to include PreHevbrio and links to recent CDC recommendation for routine HepB vaccination of adults updated its Hepatitis B and Healthcare Personnel five-page document to incorporate the use of the newest recommended hepatitis B vaccine option, PreHevbrio (VBI Vaccines). It clarifies considerations for healthcare personnel with documentation of a complete series of HepB vaccination but no documentation of protective levels of anti-HBs antibody. In addition, a link was added to the April 2022 CDC recommendation for routine HepB vaccination of all adults 19 through 59 years old.

Related Links revises “Vaccines Work!,” the CDC table showing how rates of each vaccine-preventable disease have dropped since introduction of routine vaccination updated its popular Vaccines Work! print-ready document with revised CDC data on how rates of each vaccine-preventable disease dropped after introduction of routine vaccination. 

Related Links

Back to top updates “Administering Vaccines: Dose, Route, Site, and Needle Size” table for healthcare providers and staff to include COVID-19 vaccines updated its Administering Vaccines: Dose, Routine, Site, and Needle Size table for healthcare providers and staff. The popular resource now:

  • Incorporates use of COVID-19 vaccines in infants and children age 6 months and older
  • Specifies the different types of inactivated influenza vaccines
  • Adds PreHevbrio (VBI Vaccines) to the list of hepatitis B vaccines

Related Links

Featured Resources’s new social media program highlights our educational resources; please like and share on your own channels launched a new social media program to highlight our educational resources. Our social media channels now feature our most popular printable resources and Ask the Experts questions, as well as announcements important to frontline vaccinators.

Like, follow, and share’s social media accounts and encourage colleagues and others interested in vaccination to do likewise:

Each additional follower extends the reach of our work to help healthcare professionals deliver quality vaccination services to people of all ages.

Back to top  

AIM offers new COVID-19 Vaccination Social Media Toolkit to encourage vaccination among racial and ethnic minority adults

The Association of Immunization Managers (AIM) offers a new COVID-19 Vaccination Social Media Toolkit in both English and Spanish, with tips and sample posts for encouraging COVID-19 vaccination among racial and ethnic minority adults. The messages and images in this toolkit were developed based on feedback from community health workers in Alabama, Arizona, Georgia, Florida, Kentucky, Michigan, and Texas. Additional sample messages and graphics that can be used for Facebook and Instagram Stories will be released in coming months.

If you have questions about the toolkit, want to co-brand, or need help getting started, email

Notable Publications

“Interim Guidance for Prevention and Treatment of Monkeypox in Persons with HIV Infection—United States, August 2022” published in MMWR Early Release

CDC published Interim Guidance for Prevention and Treatment of Monkeypox in Persons with HIV Infection—United States, August 2022 on August 5 in an MMWR Early Release. A portion of the summary appears below. 

A multinational monkeypox outbreak disproportionately affecting men who have sex with men, including persons with HIV infection, is ongoing worldwide....

CDC has developed clinical considerations for prevention and treatment of monkeypox in persons with HIV infection, including pre-exposure and postexposure prophylaxis with JYNNEOS vaccine, treatment with tecovirimat, and infection control....

Persons with advanced HIV might be at increased risk for severe monkeypox. Postexposure prophylaxis and antiviral treatments are available for persons with HIV infection. Prompt diagnosis and treatment and enhanced prevention efforts might reduce the risk for severe outcomes.

Access the MMWR article in HTML or PDF.

Related Links

Back to top
“Post-COVID Symptoms and Conditions among Children and Adolescents—United States, March 1, 2020–January 31, 2022” published in MMWR

CDC published Post-COVID Symptoms and Conditions among Children and Adolescents—United States, March 1, 2020–January 31, 2022 on August 5 in MMWR. A portion of the summary appears below. 

Children and adolescents might be at risk for certain post-COVID symptoms and conditions....

Compared with patients aged 0–17 years without previous COVID-19, those with previous COVID-19 had higher rates of acute pulmonary embolism (adjusted hazard ratio = 2.01), myocarditis and cardiomyopathy (1.99), venous thromboembolic event (1.87), acute and unspecified renal failure (1.32), and type 1 diabetes (1.23), all of which were rare or uncommon in this study population....

COVID-19 prevention strategies, including vaccination for all eligible persons aged ≥6 months, are critical to preventing SARS-CoV-2 infection and subsequent illness, and reducing the public health impact of post-COVID symptoms and conditions among persons aged 0–17 years.

Access the MMWR article in HTML or PDF.

Related Link

Upcoming Events

On-demand: CDC’s recorded chapter-by-chapter webinars on vaccine-preventable diseases and best practices from “The Pink Book,” now rolling out weekly; CE available 

CDC continues its 19-part pre-recorded webinar series to provide a chapter-by-chapter overview of the 14th edition of Epidemiology and Prevention of Vaccine-Preventable Diseases (also known as "The Pink Book"). 

The seventh webinar, on DTaP and Tdap, was released on August 9; no registration is required. Additional webinars will be released weekly, concluding on November 1, 2022.
Information and program details are available on CDC's Pink Book Webinars series web page.

CME, CNE, CPE, and CEU credits are available for each event. Questions about the material can be submitted to

For more upcoming events, visit our Calendar of Events.

About IZ Express

IZ Express is supported in part by Grant No. 1NH23IP922654 from CDC’s National Center for Immunization and Respiratory Diseases. Its contents are solely the responsibility of and do not necessarily represent the official views of CDC.

IZ Express Disclaimer
ISSN 2771-8085

Editorial Information

  • Editor-in-Chief
    Kelly L. Moore, MD, MPH
  • Managing Editor
    John D. Grabenstein, RPh, PhD
  • Associate Editor
    Sharon G. Humiston, MD, MPH
  • Writer/Publication Coordinator
    Taryn Chapman, MS
    Courtnay Londo, MA
  • Style and Copy Editor
    Marian Deegan, JD
  • Web Edition Managers
    Arkady Shakhnovich
    Jermaine Royes
  • Contributing Writer
    Laurel H. Wood, MPA
  • Technical Reviewer
    Kayla Ohlde

This page was updated on .